TRCT
CERO

Tower Research Capital (TRC)’s CERo Therapeutics CERO Stock Holding History

Tower Research Capital (TRC)’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,299
Closed -$6.61K – 5686
2025
Q3 		$6.61K Buy
1,299
+615
+90% +$4.52K ﹤0.01% 4150
2025
Q2 		$6.59K Buy
684
+433
+173% +$5.39K ﹤0.01% 4100
2025
Q1 		$3.66K Buy
251
+214
+578% +$8.46K ﹤0.01% 4372
2024
Q4 		$4.42K Buy
37
+35
+1,750% +$8.16K ﹤0.01% 4463
2024
Q3 		$462 Buy
+2
New +$609 ﹤0.01% 5334
2023
Q3 		– Hold
0
– -$65 – 6290
2023
Q2 		– Hold
0
– – – 5855
2023
Q1 		– Hold
0
– – – 6353
2022
Q4 		– Hold
0
– – – 6466
2022
Q3 		– Hold
0
– – – 6560
2022
Q2 		– Hold
0
– – – 5620

Tower Research Capital (TRC)'s CERO Position: Q4 2025 in Review

Tower Research Capital (TRC) sold out of CERo Therapeutics (CERO) in Q4 2025, closing a stake of 1,299 shares — an estimated $6.61K sold.

Tower Research Capital (TRC) first reported a position in CERO in Q3 2024 and held it in 5 quarters. The position peaked at $6.61K in Q3 2025. 0 funds tracked by Wall St. Rank hold CERO as of Q4 2025.

  • Tower Research Capital (TRC) reported no remaining CERo Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 1,299 CERo Therapeutics shares in Q4 2025, an estimated $6.61K.
  • Tower Research Capital (TRC) first reported a position in CERo Therapeutics in Q3 2024 and held it in 5 quarters.
  • Tower Research Capital (TRC)'s CERo Therapeutics position peaked at $6.61K in Q3 2025.
  • 0 funds tracked by Wall St. Rank held CERo Therapeutics as of Q4 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.